Lead Product(s): DYN101
Therapeutic Area: Genetic Disease
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Perceptive Advisors
Deal Size: $54.6 million Upfront Cash: Undisclosed
Deal Type: Series C Financing April 02, 2020
Funding supports ongoing Phase 1 / 2 'Unite-CNM' study of DYN101 in Patients with Myotubular and Centronuclear Myopathies.